Is FLOW a fair comparison of semaglutide against its comparator arm?

Asked 2 Dec 2025Modified 8 months agoViewed 15k times

The specifics, since they change the answer: FLOW · semaglutide.

I want to know whether there is evidence behind this or only repetition.

I have checked the obvious registries and monographs without success.

Has anyone verified this independently?

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questionssemaglutide

semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questionstirzepatide

tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions

shareeditfollowflag

askedDr_Idris_Coulibaly33k1372 Dec 2025

8Can you link the publication rather than the summary? The summary usually drops the interval. – Dr_Lena_Ostrowska 5 months ago

7Is this the randomised phase or the open-label extension? – kwn_analytical 3 months ago

add a comment

No answers yet

This question has not been answered. It has been viewed 15k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.

Linked questions

37 What should be in place before a first tirzepatide vial arrives from Shanghai?39 Would a sterility test distinguish dimerisation from a synthesis impurity in tirzepatide?34 Would you accept 97.9% on tirzepatide from ERP without a content assay?35 Does the SURMOUNT-OSA population resemble anyone asking about tirzepatide here?

PeptideMeter

Published, aggregated third-party test data and vendor ratings. Stated methodology.

Browse results

Hot on the stack

How long does survodutide stay within specification at 2–8 °C once reconstituted?25 votes · 5 answers · 52k views Would you re-test tirzepatide after ten weeks at 30 °C, or accept the original certificate?32 votes · 5 answers · 53k views What should be in place before a first cagrilintide vial arrives from Guangzhou?32 votes · 5 answers · 55k views Is there any published stability data for ecnoglutide at 2–8 °C?40 votes · 3 answers · 57k views Is there any published stability data for mazdutide at minus 20 °C?32 votes · 5 answers · 59k views How many units on a 0.3 mL insulin syringe is a 2.5 mg dose at 10 mg/mL?35 votes · 5 answers · 62k views Is peptide mapping worth paying for on top of a purity figure for ecnoglutide?41 votes · 5 answers · 65k views

The stack

Questions5.2k

Answers20k

Accepted3.1k

Unanswered739

Tags107

Users220

Vendors tracked20

Is FLOW a fair comparison of semaglutide against its comparator arm?

clinical-trials

semaglutide

tirzepatide

No answers yet

PeptideMeter - Independent Peptide Analytics

Your answer

Browse

About